- Home
- CYBR vs PODD Comparison
CYBR vs PODD Comparison
Compare CYBR & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBR
- PODD
- Stock Information
- Founded
- CYBR 1999
- PODD 2000
- Country
- CYBR Israel
- PODD United States
- Employees
- CYBR N/A
- PODD N/A
- Industry
- CYBR Computer Software: Prepackaged Software
- PODD Medical/Dental Instruments
- Sector
- CYBR Technology
- PODD Health Care
- Exchange
- CYBR Nasdaq
- PODD Nasdaq
- Market Cap
- CYBR 24.0B
- PODD 23.8B
- IPO Year
- CYBR 2014
- PODD 2007
- Fundamental
- Price
- CYBR $485.95
- PODD $333.51
- Analyst Decision
- CYBR Buy
- PODD Strong Buy
- Analyst Count
- CYBR 34
- PODD 18
- Target Price
- CYBR $434.93
- PODD $334.50
- AVG Volume (30 Days)
- CYBR 818.5K
- PODD 571.8K
- Earning Date
- CYBR 11-12-2025
- PODD 11-06-2025
- Dividend Yield
- CYBR N/A
- PODD N/A
- EPS Growth
- CYBR N/A
- PODD N/A
- EPS
- CYBR N/A
- PODD 3.32
- Revenue
- CYBR $1,200,117,000.00
- PODD $2,359,500,000.00
- Revenue This Year
- CYBR $35.80
- PODD $29.13
- Revenue Next Year
- CYBR $19.13
- PODD $18.13
- P/E Ratio
- CYBR N/A
- PODD $100.19
- Revenue Growth
- CYBR 39.45
- PODD 26.00
- 52 Week Low
- CYBR $267.18
- PODD $225.37
- 52 Week High
- CYBR $488.63
- PODD $353.50
- Technical
- Relative Strength Index (RSI)
- CYBR 77.57
- PODD 52.30
- Support Level
- CYBR $465.96
- PODD $313.24
- Resistance Level
- CYBR $478.75
- PODD $351.94
- Average True Range (ATR)
- CYBR 9.12
- PODD 10.74
- MACD
- CYBR 0.69
- PODD -3.18
- Stochastic Oscillator
- CYBR 94.40
- PODD 50.35
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader in that subsegment, with more than half of the Fortune 500 as CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While CyberArk historically sold its security solutions primarily via on-premises licenses, over the past few years it has transitioned to a subscription recurring-revenue model.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.